These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31180176)

  • 1. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
    Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
    Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
    Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
    Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
    Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
    Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
    Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.
    Shajahan-Haq AN; Cook KL; Schwartz-Roberts JL; Eltayeb AE; Demas DM; Warri AM; Facey CO; Hilakivi-Clarke LA; Clarke R
    Mol Cancer; 2014 Oct; 13():239. PubMed ID: 25339305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
    Santen R; Jeng MH; Wang JP; Song R; Masamura S; McPherson R; Santner S; Yue W; Shim WS
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):115-25. PubMed ID: 11850215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.
    Cook KL; Clarke PA; Parmar J; Hu R; Schwartz-Roberts JL; Abu-Asab M; Wärri A; Baumann WT; Clarke R
    FASEB J; 2014 Sep; 28(9):3891-905. PubMed ID: 24858277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
    Lewis-Wambi JS; Kim HR; Wambi C; Patel R; Pyle JR; Klein-Szanto AJ; Jordan VC
    Breast Cancer Res; 2008; 10(6):R104. PubMed ID: 19061505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
    Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
    Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and regulation of Cyr61 in human breast cancer cell lines.
    Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
    Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.
    Abderrahman B; Maximov PY; Curpan RF; Hanspal JS; Fan P; Xiong R; Tonetti DA; Thatcher GRJ; Jordan VC
    Mol Pharmacol; 2020 Oct; 98(4):364-381. PubMed ID: 32788222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD; Waltz PK; Kilker RL
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
    Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
    Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
    Chen X; Danes C; Lowe M; Herliczek TW; Keyomarsi K
    J Natl Cancer Inst; 2000 Sep; 92(17):1403-13. PubMed ID: 10974076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 19. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
    Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
    Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer.
    Huang D; Yang F; Wang Y; Guan X
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):148-156. PubMed ID: 28344099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.